Vaxxinity is a biotechnology business based in the US. Vaxxinity shares (VAXX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.03 – the same closing value as a week prior. Vaxxinity employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.03 |
|---|---|
| 52-week range | $0.00 - $0.50 |
| 50-day moving average | $0.01 |
| 200-day moving average | $0.01 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.45 |
Historical closes compared with the close of $0.04 from 2025-07-08
| 1 week (2025-07-03) | 33.33% |
|---|---|
| 1 month (2025-06-10) | 300.00% |
| 3 months (2025-04-10) | 300.00% |
| 6 months (2025-01-10) | -20.00% |
| 1 year (2024-07-10) | -88.93% |
|---|---|
| 2 years (2023-07-10) | -98.43% |
| 3 years (2022-07-08) | 1.9 |
| 5 years (2020-07-06) | N/A |
| Gross profit TTM | $-1,871,000 |
|---|---|
| Return on assets TTM | -48.34% |
| Return on equity TTM | -150.65% |
| Profit margin | 0% |
| Book value | $0.11 |
| Market Capitalization | $5.1 million |
TTM: trailing 12 months
We're not expecting Vaxxinity to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Vaxxinity's shares have ranged in value from as little as $0 up to $0.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Vaxxinity's is -23.056. This would suggest that Vaxxinity's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vaxxinity has bucked the trend.
To put Vaxxinity's beta into context you can compare it against those of similar companies.
Vaxxinity, Inc. , a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313, which is in Phase 1 clinical trial targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. It has a collaboration agreement with the University of Florida, University of Central Florida, and the University of Southampton. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. .
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Discover the best stock picking services based on expert analysis, pricing, and strategy fit. Compare top tools to find the right service for your investing style in 2025.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
We’ve rounded up stats on some of the most popular oil stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .